Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key role in the development of antiphospholipid syndrome (APS). Recent findings strengthened the implication of B cells with the description of specific B cell phenotype abnormalities and inborn errors of immunity involving B cell signaling in APS patients. In addition, it has been shown in preclinical models that cross-reactivity between APS autoantigens and mimotopes expressed by human gut commensals can lead to B cell tolerance breakdown and are sufficient for APS development. However, B cell targeting therapies are surprisingly not as effective as expected in APS compared to other autoimmune diseases. Elucidation of the B cell tolerance breakdown mechanisms in APS patients may help to develop and guide the use of novel therapeutic agents that target B cells or specific immune pathway. Copyright © 2021. Published by Elsevier B.V.

Citation

Yannick Dieudonné, Aurélien Guffroy, Vincent Poindron, Pauline Soulas Sprauel, Thierry Martin, Anne-Sophie Korganow, Vincent Gies. B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmunity reviews. 2021 May;20(5):102798

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33722752

View Full Text